Overview

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.

Phase:

Phase 1

Details

Lead Sponsor:

Semafore Pharmaceuticals

Collaborator:

SignalRX Pharmaceuticals, Inc.